Free Trial
NASDAQ:QURE

uniQure Q3 2023 Earnings Report

uniQure logo
$13.88 +0.11 (+0.79%)
As of 03:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

uniQure EPS Results

Actual EPS
-$1.88
Consensus EPS
-$1.49
Beat/Miss
Missed by -$0.39
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$1.41 million
Expected Revenue
$3.33 million
Beat/Miss
Missed by -$1.92 million
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

uniQure Earnings Headlines

uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen
Cantor Fitzgerald Predicts Weaker Earnings for uniQure
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Leerink Partnrs Has Bullish Estimate for uniQure Q3 Earnings
William Blair Has Positive Outlook for uniQure Q3 Earnings
What is HC Wainwright's Forecast for uniQure Q3 Earnings?
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat